SPOP the mutation

SPOP the mutation

Prostate cancers with mutations to a protein called SPOP use an error-prone method to repair broken DNA strands.

Bibliographic Details
Main Authors:	Leah Rider, Scott D Cramer
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2015-10-01
Series:	eLife
Subjects:	prostate cancer cancer genomic SPOP DNA repair
Online Access:	https://elifesciences.org/articles/11760

Similar Items

SPOP mutation leads to genomic instability in prostate cancer
by: Gunther Boysen, et al.
Published: (2015-09-01)

The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis
by: Jinlu Ma, et al.
Published: (2021-07-01)

Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis
by: Ding Guanxiong, et al.
Published: (2020-10-01)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
by: Jie Zhou, et al.
Published: (2022-08-01)

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression
by: Jian Ma, et al.
Published: (2018-07-01)

The emerging role of SPOP protein in tumorigenesis and cancer therapy
by: Yizuo Song, et al.
Published: (2020-01-01)

SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway
by: Zhenzhen Luo, et al.
Published: (2021-10-01)

Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
by: Hui Wang, et al.
Published: (2017-08-01)

The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
by: Yuqian Yan, et al.
Published: (2019-09-01)

G3BP1 modulates SPOP to promote prostate tumorigenesis
by: Chandrani Mukhopadhyay, et al.
Published: (2022-12-01)

SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF
by: Kai Feng, et al.
Published: (2022-12-01)

SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions
by: Qiwei Jiang, et al.
Published: (2021-08-01)

SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression
by: Lixia Wang, et al.
Published: (2020-06-01)

Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma
by: Wei Yan, et al.
Published: (2022-06-01)

Nabais Sa-de Vries Syndrome and Thalassemia: An Undiscovered Concurrence of SPOP and HBB Genetic Mutation
by: Muhammad Matloob Alam, et al.
Published: (2024-04-01)

Association of SPOP Expression with the Immune Response to <i>Salmonella</i> Infection in Chickens
by: Fei Wang, et al.
Published: (2020-02-01)

SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization
by: Jiangchun Wu, et al.
Published: (2022-08-01)

Nabais Sa‐de Vries syndrome in a Chinese infant associated with a novel SPOP mutation: A clinical study and genetic report
by: Wenjing Hu, et al.
Published: (2022-12-01)

SPOP and OTUD7A Control EWS–FLI1 Protein Stability to Govern Ewing Sarcoma Growth
by: Siyuan Su, et al.
Published: (2021-07-01)

TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer
by: Xiaofeng Dai, et al.
Published: (2024-03-01)

Speckle-type POZ protein functions as a tumor suppressor in non-small cell lung cancer due to DNA methylation
by: Sumei Yao, et al.
Published: (2018-12-01)

Cullin 3 ubiquitin ligases in cancer biology: functions and therapeutic implications
by: Hsin-Yi eChen, et al.
Published: (2016-05-01)

Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer
by: Fidelis Charles Bugoye, et al.
Published: (2023-09-01)

Prostate cancer and PARP inhibitors: progress and challenges
by: Diego Teyssonneau, et al.
Published: (2021-03-01)

miR‐372 and miR‐373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways
by: Lu‐Qin Wang, et al.
Published: (2018-11-01)

The prevalence of lynch syndrome (DNA mismatch repair protein deficiency) in patients with primary localized prostate cancer using immunohistochemistry screening
by: Suguru Oka, et al.
Published: (2023-10-01)

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
by: Frank Jacobsen, et al.
Published: (2017-07-01)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
by: Dai Koguchi, et al.
Published: (2021-09-01)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
by: Yuqian Yan, et al.
Published: (2018-03-01)

Apoptosis, genomic integrity, and cancer /
by: Van Lancker, Julien L., 1924-
Published: (2006)

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients
by: Yixiao Liu, et al.
Published: (2023-03-01)

Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity
by: Nicholas Sciascia, et al.
Published: (2020-02-01)

Editorial: Protecting the code: DNA double-strand break repair pathway choice
by: Jenny Kaur Singh, et al.
Published: (2022-08-01)

Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
by: Yukiyoshi Hirayama, et al.
Published: (2022-11-01)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
by: David Hsiehchen, et al.
Published: (2020-06-01)

Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage
by: Ding-fang Zhang, et al.
Published: (2021-07-01)

Germline mutations of TP53 gene can be a key factor in prostate cancer genesis
by: Kawtar Aboulalaa, et al.
Published: (2024-10-01)

Tissue-Specific Effects of Aging on Repeat-Mediated Mutation Hotspots In Vivo
by: Alexandra M. D’Amico, et al.
Published: (2024-11-01)

Cancer Risks Linked to the Bad Luck Hypothesis and Epigenomic Mutational Signatures
by: José E. Belizário
Published: (2018-07-01)

Use of PARP inhibitors in prostate cancer: from specific to broader application
by: Zhenting Zhang, et al.
Published: (2023-04-01)